» Articles » PMID: 39865094

Standard Operating Procedure Combined with Comprehensive Quality Control System for Multiple LC-MS Platforms Urinary Proteomics

Overview
Journal Nat Commun
Date 2025 Jan 26
PMID 39865094
Authors
Affiliations
Soon will be listed here.
Abstract

Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography-mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms. To systematically analyze and assess the quality of large-scale urinary proteomics data, we develop a comprehensive quality control (QC) system named MSCohort, which extracted 81 metrics for individual experiment and the whole cohort quality evaluation. Additionally, we present a standard operating procedure (SOP) for high-throughput urinary proteome analysis based on MSCohort QC system. Our study involves 20 LC-MS platforms and reveals that, when combined with a comprehensive QC system and a unified SOP, the data generated by data-independent acquisition (DIA) workflow in urine QC samples exhibit high robustness, sensitivity, and reproducibility across multiple LC-MS platforms. Furthermore, we apply this SOP to hybrid benchmarking samples and clinical colorectal cancer (CRC) urinary proteome including 527 experiments. Across three different LC-MS platforms, the analyses report high quantitative reproducibility and consistent disease patterns. This work lays the groundwork for large-scale clinical urinary proteomics studies spanning multiple platforms, paving the way for precision medicine research.

References
1.
Geyer P, Holdt L, Teupser D, Mann M . Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017; 13(9):942. PMC: 5615924. DOI: 10.15252/msb.20156297. View

2.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

3.
Jiang Y, Rex D, Schuster D, Neely B, Rosano G, Volkmar N . Comprehensive Overview of Bottom-Up Proteomics Using Mass Spectrometry. ACS Meas Sci Au. 2024; 4(4):338-417. PMC: 11348894. DOI: 10.1021/acsmeasuresciau.3c00068. View

4.
Wang X, Baek S, Eling T . The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol. 2012; 85(5):597-606. PMC: 3566326. DOI: 10.1016/j.bcp.2012.11.025. View

5.
Guo Z, Wang Z, Lu C, Yang S, Sun H, Reziw . Analysis of the differential urinary protein profile in IgA nephropathy patients of Uygur ethnicity. BMC Nephrol. 2018; 19(1):358. PMC: 6295011. DOI: 10.1186/s12882-018-1139-3. View